Abbvie Inc Stock Today

ABBV Stock  USD 177.30  1.72  0.98%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 10

 
High
 
Low
Low
AbbVie is selling for under 177.30 as of the 23rd of December 2024; that is 0.98 percent increase since the beginning of the trading day. The stock's lowest day price was 170.66. AbbVie has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Note, on November 22, 2024, Representative Marjorie Taylor Greene of US Congress acquired under $15k worth of AbbVie Inc's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
2nd of January 2013
Category
Healthcare
Classification
Health Care
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Abbvie operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 1.77 B outstanding shares of which 19.32 M shares are presently shorted by private and institutional investors with about 2.46 trading days to cover. More on AbbVie Inc

Moving together with AbbVie Stock

  0.7ME 23Andme HoldingPairCorr
  0.76VALN Valneva SE ADRPairCorr

Moving against AbbVie Stock

  0.76VCEL Vericel Corp OrdPairCorr
  0.66VCYT VeracytePairCorr
  0.59DSGN Design TherapeuticsPairCorr
  0.49DRTS Alpha Tau MedicalPairCorr
  0.44VANI Vivani MedicalPairCorr
  0.44CDIOW Cardio DiagnosticsPairCorr

AbbVie Stock Highlights

ESG Sustainability
Environmental
Governance
Social
ChairmanCarlos Alban
Thematic Ideas
(View all Themes)
Old Names[AbbVie Inc, AbbVie Inc]
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Institutional, SP 500 Index, SP 100 Index, SP 100, Dow Jones Biotechnology, ARCA Pharmaceutical, Cannabis, Macroaxis Index, Giant Impact, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal TestingCatholic
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Assets0.03430.0361
Notably Down
Slightly volatile
Asset Turnover0.570.4032
Significantly Up
Slightly volatile
Gross Profit Margin0.80.6242
Significantly Up
Slightly volatile
Total Current Liabilities39.7 B37.8 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total55.5 B86.5 B
Way Down
Slightly volatile
Total Assets81.2 B134.7 B
Way Down
Slightly volatile
Total Current Assets23.5 B33 B
Way Down
Slightly volatile
Total Cash From Operating Activities12.6 B22.8 B
Way Down
Slightly volatile
Debt Levels
AbbVie can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AbbVie's financial leverage. It provides some insight into what part of AbbVie's total assets is financed by creditors.
Liquidity
AbbVie Inc currently holds 59.38 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about AbbVie's use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

611.53 Million
AbbVie Inc (ABBV) is traded on New York Stock Exchange in USA. It is located in 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 and employs 50,000 people. AbbVie is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 310.27 B. AbbVie Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.77 B outstanding shares of which 19.32 M shares are presently shorted by private and institutional investors with about 2.46 trading days to cover. AbbVie Inc currently holds about 11.88 B in cash with 22.84 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.72.
Check AbbVie Probability Of Bankruptcy
Ownership Allocation
AbbVie holds a total of 1.77 Billion outstanding shares. The majority of AbbVie Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AbbVie Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AbbVie. Please pay attention to any change in the institutional holdings of AbbVie Inc as this could imply that something significant has changed or is about to change at the company. On November 22, 2024, Representative Marjorie Taylor Greene of US Congress acquired under $15k worth of AbbVie Inc's common stock.
Check AbbVie Ownership Details

AbbVie Stock Institutional Holders

InstituionRecorded OnShares
Northern Trust Corp2024-09-30
19.5 M
Bank Of New York Mellon Corp2024-09-30
17.1 M
Capital World Investors2024-09-30
15.5 M
Legal & General Group Plc2024-09-30
15.2 M
Franklin Resources Inc2024-09-30
13.9 M
Ameriprise Financial Inc2024-09-30
13.8 M
Fmr Inc2024-09-30
13.6 M
Ubs Group Ag2024-09-30
11.5 M
Goldman Sachs Group Inc2024-09-30
10.7 M
Vanguard Group Inc2024-09-30
171.6 M
Blackrock Inc2024-06-30
136.4 M
View AbbVie Diagnostics

AbbVie Historical Income Statement

At this time, AbbVie's Depreciation And Amortization is fairly stable compared to the past year. EBIT is likely to climb to about 10.7 B in 2024, whereas Selling General Administrative is likely to drop slightly above 7.8 B in 2024. View More Fundamentals

AbbVie Stock Against Markets

AbbVie Corporate Directors

Brett HartIndependent DirectorProfile
Roxanne AustinIndependent DirectorProfile
Edward RappIndependent DirectorProfile
Frederick WaddellIndependent DirectorProfile

Already Invested in AbbVie Inc?

The danger of trading AbbVie Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AbbVie is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AbbVie. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AbbVie Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.